LOTTE Biologics

LOTTE BIOLOGICS has a campus for biopharmaceutical production in the Syracuse of U.S. and is in the process of constructing a bio campus in the Songdo, Korea which will be operational by 2027.

• Two sites in the U.S. and Korea with a unified quality system,
• 20 years of commercial biologics manufacturing
• Antibody and  ADC production in one U.S. location

• Syracuse  Bio Campus : 40KL (5KL x 8)
• Songdo Bio Campus : 120KL (15KL x 8)